Drug-pricing collution lawsuit widens to include more companies and drugs; New Jersey and Alaska also file lawsuits against Purdue Pharma for opioid marketing tactics; and the preterm birth rate in the United States increases.
A lawsuit brought by state attorneys general accusing companies of drug-pricing collusion has increased the number of companies named as defendants and expanded the number of drugs.
that the lawsuit now accuses 18 companies and 15 medicines, in addition to targeting 2 individual executives at Mylan and Emcure Pharmaceuticals. The lawsuit claims the drug makers agreed on dividing up the market and sometimes on prices increases. The original complaint only targeted 6 companies and 2 drugs.
The list of states and municipalities suing Purdue Pharma for misleading sales tactics for opioid painkillers has grown to include New Jersey and Alaska. Both states’ attorneys general accused the company of aggressive and misleading tactics that fueled the opioid and heroin addiction crisis, reported The Wall Street Journal. Purdue is also being sued by 9 other states, and New Jersey is also suing Insys Therapeutics for marketing of the painkiller Subsys, which was only approved to be marketed to cancer patients.
For the second year, the preterm birth rate has risen in the United States following nearly a decade of declines. According to STAT, minorities are suffering a disproportionate share of preterm births and rates in some parts of the United States are similar to those in undeveloped countries in Africa and the Middle East. Compared with white women, black women were 49% more likely to give birth prematurely and American Indian and Native Alaskan women were 18% more likely. Cleveland had the highest preterm birth rate of 100 cities examined.
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More